Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1999 1
2004 2
2006 1
2007 1
2008 2
2009 2
2010 4
2011 3
2012 7
2013 7
2014 5
2015 3
2016 5
2017 4
2018 4
2019 3
2020 2
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Rapid switching from levetiracetam to brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study.
Watkins LV, Dunstall H, Musicha C, Lawthom C, John K, Bright C, Richings C, Harding K, Moon S, Pape SE, Winterhalder R, Allgar V, Thomas RH, McLean B, Laugharne R, Shankar R. Watkins LV, et al. Among authors: winterhalder r. J Neurol. 2023 Dec;270(12):5889-5902. doi: 10.1007/s00415-023-11959-w. Epub 2023 Aug 23. J Neurol. 2023. PMID: 37610448
Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.
Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins L, Purandare KN, Eyeoyibo M, Scheepers M, Lines G, Winterhalder R, Ashby S, De Silva R, Miller J, Philpott DE, Ashwin C, Howkins J, Slater H, Medhurst D, Shankar R. Sun JJ, et al. Among authors: winterhalder r. J Neurol. 2022 May;269(5):2750-2760. doi: 10.1007/s00415-021-10938-3. Epub 2022 Jan 24. J Neurol. 2022. PMID: 35067759
Correction to: Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.
Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins L, Purandare KN, Eyeoyibo M, Scheepers M, Lines G, Winterhalder R, Ashby S, De Silva R, Miller J, Philpott DE, Ashwin C, Howkins J, Slater H, Medhurst D, Shankar R. Sun JJ, et al. Among authors: winterhalder r. J Neurol. 2022 May;269(5):2761. doi: 10.1007/s00415-022-11012-2. J Neurol. 2022. PMID: 35247093 No abstract available.
Antiangiogenic treatment for multiple CNS hemangioblastomas.
Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M. Riklin C, et al. Among authors: winterhalder r. Onkologie. 2012;35(7-8):443-5. doi: 10.1159/000341075. Epub 2012 Jul 3. Onkologie. 2012. PMID: 22846977 Free article.
56 results